导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.47% | 2858/4773 |
| 近一周 | -0.65% | 705/5458 |
| 近一月 | -4.59% | 2951/5421 |
| 近一季 | 11.40% | 171/5205 |
| 近半年 | -1.42% | 1821/4920 |
| 近一年 | -14.14% | 3666/4361 |
| 近两年 | 22.30% | 2623/2954 |
| 近三年 | -14.88% | 2094/2253 |
| 成立以来 | -62.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.75% 2893/4961 |
-6.70% 3737/5312 |
- - |
- - |
| 2025 | 3.77% 3096/4813 |
2.89% 1242/3635 |
-1.53% 3191/4076 |
17.19% 2542/4524 |
-12.60% 4263/4813 |
| 2024 | -15.28% 2471/3463 |
-13.73% 2493/2808 |
-10.45% 2445/3014 |
21.31% 600/3129 |
-9.60% 2940/3463 |
| 2023 | -22.10% 1918/2656 |
-2.31% 1959/2280 |
-14.41% 2238/2385 |
-1.34% 505/2515 |
-5.57% 1401/2655 |
| 2022 | -23.36% 1129/2207 |
-16.28% 1120/1919 |
3.37% 1163/2016 |
-17.96% 1666/2113 |
7.95% 279/2208 |
| 2021 | -14.24% 1145/1822 |
-3.66% 820/1255 |
21.45% 134/1330 |
-17.05% 1406/1466 |
-11.65% 1612/1822 |
| 2020 | 80.80% 39/1250 |
11.85% 14/1028 |
38.61% 7/1067 |
4.27% 960/1164 |
11.84% 517/1184 |
| 2019 | 50.02% 102/1092 |
28.53% 304/754 |
-3.59% 402/804 |
14.18% 19/850 |
6.03% 660/918 |
| 2018 | -11.52% 75/834 |
- - |
- - |
- - |
-14.10% 570/691 |
| 2017 | -11.36% 544/714 |
- - |
- - |
- - |
- - |
| 2016 | -25.47% 483/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝医疗ETF联接A VS. 长安沪深300非周期A(740101) |